Neovacs S.A. (ALNEV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neovacs S.A. (ALNEV) has a cash flow conversion efficiency ratio of -0.129x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.43 Million ≈ $-2.85 Million USD) by net assets (€18.89 Million ≈ $22.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neovacs S.A. - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Neovacs S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Neovacs S.A. (ALNEV) total liabilities for a breakdown of total debt and financial obligations.
Neovacs S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neovacs S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Peak Processing Limited
AU:PKP
|
14.646x |
|
CuriosityStream Inc
NASDAQ:CURIW
|
0.093x |
|
Adheris Health Limited
AU:AHE
|
-5.131x |
|
PetroFrontier Corp
V:PFC
|
-0.745x |
|
NRx Pharmaceuticals Inc
NASDAQ:NRXPW
|
0.233x |
|
Tarrina Resources Limited
AU:TR8
|
0.092x |
|
Versus Systems Inc
NASDAQ:VSSYW
|
0.007x |
|
European Resources Limited
AU:ERE
|
N/A |
Annual Cash Flow Conversion Efficiency for Neovacs S.A. (2007–2024)
The table below shows the annual cash flow conversion efficiency of Neovacs S.A. from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see ALNEV market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €18.06 Million ≈ $21.12 Million |
€-3.60 Million ≈ $-4.21 Million |
-0.199x | -356.68% |
| 2023-12-31 | €43.82 Million ≈ $51.23 Million |
€-1.91 Million ≈ $-2.24 Million |
-0.044x | +56.59% |
| 2022-12-31 | €44.23 Million ≈ $51.71 Million |
€-4.45 Million ≈ $-5.20 Million |
-0.101x | +55.44% |
| 2021-12-31 | €43.90 Million ≈ $51.32 Million |
€-9.91 Million ≈ $-11.58 Million |
-0.226x | +56.14% |
| 2020-12-31 | €10.98 Million ≈ $12.84 Million |
€-5.65 Million ≈ $-6.61 Million |
-0.515x | +82.61% |
| 2019-12-31 | €2.74 Million ≈ $3.20 Million |
€-8.10 Million ≈ $-9.47 Million |
-2.958x | +45.82% |
| 2018-12-31 | €2.44 Million ≈ $2.85 Million |
€-13.31 Million ≈ $-15.56 Million |
-5.461x | +67.61% |
| 2017-12-31 | €845.75K ≈ $988.77K |
€-14.26 Million ≈ $-16.67 Million |
-16.857x | -92.46% |
| 2016-12-31 | €1.26 Million ≈ $1.47 Million |
€-11.00 Million ≈ $-12.86 Million |
-8.759x | -591.16% |
| 2015-12-31 | €6.07 Million ≈ $7.09 Million |
€-7.69 Million ≈ $-8.99 Million |
-1.267x | +12.37% |
| 2014-12-31 | €5.57 Million ≈ $6.51 Million |
€-8.05 Million ≈ $-9.41 Million |
-1.446x | +28.13% |
| 2013-12-31 | €3.48 Million ≈ $4.07 Million |
€-7.00 Million ≈ $-8.18 Million |
-2.012x | -15.00% |
| 2012-12-31 | €3.62 Million ≈ $4.23 Million |
€-6.33 Million ≈ $-7.40 Million |
-1.749x | -114.30% |
| 2011-12-31 | €10.57 Million ≈ $12.36 Million |
€-8.63 Million ≈ $-10.09 Million |
-0.816x | +16.59% |
| 2010-12-31 | €8.27 Million ≈ $9.67 Million |
€-8.10 Million ≈ $-9.47 Million |
-0.979x | -104.34% |
| 2009-12-31 | €-352.58K ≈ $-412.20K |
€-7.95 Million ≈ $-9.29 Million |
22.549x | +3373.12% |
| 2008-12-31 | €6.51 Million ≈ $7.61 Million |
€-4.49 Million ≈ $-5.25 Million |
-0.689x | +68.57% |
| 2007-12-31 | €1.97 Million ≈ $2.30 Million |
€-4.32 Million ≈ $-5.05 Million |
-2.192x | -- |
About Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more